Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Drug
IBD
Inflammatory Bowel Diseases
Interleukin Agonist
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
11
11
2019
revised:
25
01
2020
accepted:
14
02
2020
pubmed:
29
2
2020
medline:
19
8
2021
entrez:
29
2
2020
Statut:
ppublish
Résumé
A subset of patients with Crohn's disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses. We performed a retrospective study to determine the effectiveness of ustekinumab dose interval shortening, collecting data from 506 patients with CD who received subcutaneous ustekinumab 90 mg every 8 weeks at a single center. We obtained data from 110 patients who initially received subcutaneous ustekinumab 90 mg every 8 weeks and then had their interval shortened to every 4 weeks. Harvey Bradshaw Index (HBI) scores before and after the dose interval shortening was available for 78 patients in the cohort (71%), levels of C-reactive protein (CRP) for 60 patients (55%), and levels of fecal calprotectin for 8 patients (7%). Following dose interval shortening, the patients' median HBI decreased from 4.5 to 3 (P = .002), the median level of CRP decreased from 8 mg/L to 3 mg/L (P = .031), and median level of fecal calprotectin decreased from 378 μg/g to 157 μg/g (P = .57). Among patients who had an HBI >4, a level of CRP ≥5mg/dL, a level of fecal calprotectin >250ug/g, or endoscopic evidence for disease activity before dose interval shortening, after the dose interval was shortened, 28% achieved clinical remission (an HBI score ≤4), 22% had a normal level of CRP (<5 mg/dL), 50% had reduced levels of fecal calprotectin, and 36% achieved endoscopic remission. Shortening the ustekinumab 90 mg dose interval to 4 weeks for patients with CD who did not respond to doses every 8 weeks improved clinical and biological indices of disease activity. Patients who lose response to the standard dose of ustekinumab might benefit from dose interval shortening, which was effective and safe.
Sections du résumé
BACKGROUND & AIMS
A subset of patients with Crohn's disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses.
METHODS
We performed a retrospective study to determine the effectiveness of ustekinumab dose interval shortening, collecting data from 506 patients with CD who received subcutaneous ustekinumab 90 mg every 8 weeks at a single center. We obtained data from 110 patients who initially received subcutaneous ustekinumab 90 mg every 8 weeks and then had their interval shortened to every 4 weeks. Harvey Bradshaw Index (HBI) scores before and after the dose interval shortening was available for 78 patients in the cohort (71%), levels of C-reactive protein (CRP) for 60 patients (55%), and levels of fecal calprotectin for 8 patients (7%).
RESULTS
Following dose interval shortening, the patients' median HBI decreased from 4.5 to 3 (P = .002), the median level of CRP decreased from 8 mg/L to 3 mg/L (P = .031), and median level of fecal calprotectin decreased from 378 μg/g to 157 μg/g (P = .57). Among patients who had an HBI >4, a level of CRP ≥5mg/dL, a level of fecal calprotectin >250ug/g, or endoscopic evidence for disease activity before dose interval shortening, after the dose interval was shortened, 28% achieved clinical remission (an HBI score ≤4), 22% had a normal level of CRP (<5 mg/dL), 50% had reduced levels of fecal calprotectin, and 36% achieved endoscopic remission.
CONCLUSIONS
Shortening the ustekinumab 90 mg dose interval to 4 weeks for patients with CD who did not respond to doses every 8 weeks improved clinical and biological indices of disease activity. Patients who lose response to the standard dose of ustekinumab might benefit from dose interval shortening, which was effective and safe.
Identifiants
pubmed: 32109634
pii: S1542-3565(20)30205-6
doi: 10.1016/j.cgh.2020.02.035
pmc: PMC8665415
mid: NIHMS1758782
pii:
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
C-Reactive Protein
9007-41-4
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104-110Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK042086
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Clin Drug Investig. 2016 Nov;36(11):913-923
pubmed: 27422740
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Aliment Pharmacol Ther. 2011 May;33(9):987-95
pubmed: 21366636
J Gastroenterol. 2017 May;52(5):535-554
pubmed: 28275925
Am J Gastroenterol. 2009 Mar;104(3):760-7
pubmed: 19174781
Am J Gastroenterol. 2010 May;105(5):1133-9
pubmed: 20145610
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508
Inflamm Bowel Dis. 2015 Jul;21(7):1709-18
pubmed: 25901974
Am J Gastroenterol. 2011 Apr;106(4):674-84
pubmed: 21407178
Inflamm Bowel Dis. 2012 Feb;18(2):349-58
pubmed: 22021134
Inflamm Bowel Dis. 2018 Oct 12;24(11):2461-2467
pubmed: 29788240
Gut. 2014 Dec;63(12):1843-53
pubmed: 24970900
Inflamm Bowel Dis. 2016 Jul;22(7):1662-9
pubmed: 27306072
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Clin Gastroenterol Hepatol. 2016 Feb;14(2):251-8.e1-2
pubmed: 26545802
Inflamm Bowel Dis. 2017 May;23(5):833-839
pubmed: 28328624
Clin Pharmacol Ther. 2012 Apr;91(4):635-46
pubmed: 22357456
Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2
pubmed: 26538204